Literature DB >> 2719893

The tubular excretion of benzylpenicillin in patients with cystic fibrosis.

J W Bins1, H Mattie.   

Abstract

1. The tubular excretion of benzylpenicillin (BP) was investigated in six volunteers with cystic fibrosis. 2. The volunteers received a continuous infusion of BP at increasing infusion rates in order to maintain constant plasma concentrations at three different levels. Blood and urine samples were taken every 30 min. Sufficient urinary flow was ensured by a saline infusion (500 ml h-1). 3. The renal clearance of BP was calculated for the non-protein bound fraction of the drug. 4. Tubular clearance and tubular excretion rate were estimated from the renal clearance of the antibiotic minus the glomerular filtration rate; the latter was considered to be equal to creatinine clearance. 5. The data were analysed according to a Scatchard plot and values for ECu50 and maximal tubular excretion rate were calculated. The mean value of ECu50 was 89 +/- 24 (mg l-1 +/- s.d.) and that for the maximal tubular excretion rate was 2603 +/- 714 (mg h-1 +/- s.d.). The latter value was significantly less than that found in a previous study of healthy volunteers, but the ECu50 was similar. 6. It is concluded that the tubular excretory capacity for BP is decreased in patients with cystic fibrosis in direct relation to their low body weight.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719893      PMCID: PMC1379825          DOI: 10.1111/j.1365-2125.1989.tb05367.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Saturation of the tubular excretion of beta-lactam antibiotics.

Authors:  J W Bins; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

2.  Bioavailability of oral antibiotics in cystic fibrosis.

Authors:  J P Guggenbichler; G Kienel
Journal:  Monogr Paediatr       Date:  1979

Review 3.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 4.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

5.  Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis.

Authors:  W J Jusko; L L Mosovich; L M Gerbracht; M E Mattar; S J Yaffe
Journal:  Pediatrics       Date:  1975-12       Impact factor: 7.124

6.  Pharmacokinetics of azlocillin in children with cystic fibrosis.

Authors:  T Bergan; H Michalsen
Journal:  Arzneimittelforschung       Date:  1979

7.  Pharmacokinetics of methicillin in patients with cystic fibrosis.

Authors:  S J Yaffe; L M Gerbracht; L L Mosovich; M E Mattar; M Danish; W J Jusko
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

8.  Cloxacillin absorption and disposition in cystic fibrosis.

Authors:  M Spino; R P Chai; A F Isles; J J Thiessen; A Tesoro; R Gold; S M MacLeod
Journal:  J Pediatr       Date:  1984-11       Impact factor: 4.406

  8 in total
  2 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.